title: Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study.
abstract: Allergic conjunctivitis (AC) is a disease of various agents that affects the physical and mental health of children. Although the most effective therapy has not been found so far, it is essential to explore the considerable therapeutic method. We compared the clinical efficacy of olopatadine, emedastine, loteprednol etabonate (LE), and vehicle for treating seasonal allergic conjunctivitis (SAC) in Chinese children.
  
  
  
  Eighty cases of 160 eyes aged from 5 to 10 years with SAC were available and those subjects were randomly distributed into 4 groups. Both their eyes received olopatadine hydrochloride 0.1% twice a day, emedastine difumarate 0.05% twice a day, or LE 0.5% 4 times a day, respectively, whereas those of the control group received artificial tears (AT) 0.5% 3 times a day. This study was conducted successfully and the observations were collected before treatment and on day 8 (±1 day) and day 15 (±2 days) afterward. The principal measurement of efficacy was focused on the signs and symptoms of the subjects, evaluated before and after treatment, in addition to visual acuity (VA) and fundus oculi.
  
  
  
  On day 8 (±1 day) and day 15 (±2 days), all the antiallergic agents were found to be more effective than vehicle (p < 0.05) in terms of all the symptoms and signs. However, there was no statistical significance (p ≥ 0.05) shown among the treatment groups. There were no evident changes in VA and no clinically significant changes were observed in fundus oculi.
  
  
  
  After the treatment, the efficacy presented a similar distribution among the trial groups.
authors.affiliation: Department of Ophthalmology, the Second Hospital Affiliated to Dalian Medical University, Dalian, China.
authors.forename: Rui-Fen
authors.initials: RF
authors.lastname: Liu
authors.affiliation: Department of Ophthalmology, the Second Hospital Affiliated to Dalian Medical University, Dalian, China.
authors.forename: Xiao-Xuan
authors.initials: XX
authors.lastname: Wu
authors.affiliation: Department of Ophthalmology, the Second Hospital Affiliated to Dalian Medical University, Dalian, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Ophthalmology, the Second Hospital Affiliated to Dalian Medical University, Dalian, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Gao
authors.affiliation: Department of Ophthalmology, the Second Hospital Affiliated to Dalian Medical University, Dalian, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhou
authors.affiliation: Department of Ophthalmology, the Second Hospital Affiliated to Dalian Medical University, Dalian, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Zhao
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D044466:Asian People; D001562:Benzimidazoles / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069559:Loteprednol Etabonate / Q000627:therapeutic use*; D008297:Male; D000069605:Olopatadine Hydrochloride / Q000627:therapeutic use*; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D001562:Benzimidazoles; D000069605:Olopatadine Hydrochloride; C043345:emedastine; D000069559:Loteprednol Etabonate
keywords: LE; SAC; efficacy; emedastine difumarate; olopatadine hydrochloride; vehicle